Publications

Chest radiography is a poor predictor of respiratory symptoms and functional impairment in survivors of severe COVID-19 pneumonia 

This article shares persistent symptoms, adverse mental health outcomes and physiological impairment are common 2 months after severe COVID-19 pneumonia. Read more.

The following publications highlight some of the exceptional research activity taking place within our partner organisations in the field of haematology. This work is helping drive meaningful innovation and improve outcomes for patient’s in our local communities and beyond.

An epitope-based approach to use of HLA matched platelets for transfusion: a noninferiority, cross-over, randomised trial 

This reports the first ever randomised, double-blind, non-inferiority, cross-over trial comparing HLA epitope-matched (HEM) platelets with HLA standard antigen-matched (HSM) platelet transfusions. Read more.

Postdischarge venous thromboembolism following hospital admission with COVID-19 

This finds the rate of symptomatic postdischarge thromboembolism (VTE) following hospitalization with COVID-19 is low. Read more.

Hypercoagulability and Anticoagulation in Patients With COVID-19 Requiring Renal Replacement Therapy 

This review presents the current understanding of the coagulopathy associated with COVID-19, the risk of venous thrombosis, and the impact of this on management of RRT in critically ill patients with COVID-19. Read more.

Pulmonary embolism in hospitalised patients with COVID-19 

This highlights COVID-19 is associated with a higher rate of pulmonary embolism – blocked blood vessels in lungs - particularly in critically-ill patients. Read more.

A perfect storm: Root cause analysis of supra-therapeutic anticoagulation with vitamin K antagonists during the COVID-19 pandemic 

This data reveals a significant increase in high international normalised ratio results during the COVID-19 pandemic, with the majority occurring after the introduction of a lockdown. Read more.

Are apixaban and rivaroxaban distributed into human breast milk to clinically relevant concentrations?

This study is the first to report the concentration-time profiles for apixaban and rivaroxaban in human plasma and breast milk over a 24-hour period after a single dose. Read more.